The PRWIRE Press Releases https:// 2017-12-03T19:59:00Z Wrays appoints Dr Linda Kennaugh and Craig Humphris to its board of directors 2017-12-03T19:59:00Z wrays-appoints-dr-linda-kennaugh-and-craig-humphris-to-its-board-of-directors PERTH, AUSTRALIA – 4 December 2017 – Wrays Pty Ltd, one of Australia’s largest independent intellectual property firms, today announced that it has appointed Dr Linda Kennaugh and Craig Humphris to its board of directors. Dr Kennaugh is a Principal in Wrays’ Perth office, and is the first female to join Wrays’ board. Mr Humphris is a Principal in Wrays’ Adelaide office, and is the first board member to be based outside of Western Australia. “Both Linda and Craig are proven performers who have built their own practices and made a significant contribution to our clients’ success and the firm’s continued growth,” says Wrays chairman Gary Cox. “Their appointments reflect the growth and evolution of Wrays into a diverse, national firm. It is an important milestone in our progress, and I’m confident Linda and Craig will bring new perspectives and ideas to the board to help us better serve our clients and further expand our horizons,” he added. Dr Kennaugh practises predominantly in life sciences and pharmaceuticals patents across Australia and New Zealand for both local and overseas clients. Her expertise encompasses gaining patent protection, enforcement of patent rights, and assisting with patent litigation. Prior to joining Wrays in 1999, Dr Kennaugh spent ten years in research. She holds a PhD in Biochemistry and a Bachelor of Science with First Class Honours in Biochemistry from the University of Western Australia. “It’s an honour to become part of the board and I’m looking forward to putting my years of experience in both research and the patent profession towards this new opportunity. As the first female appointee, I’m pleased that Wrays and the industry as a whole, is making strides towards reflecting the diversity and contributions of all people within our profession,” says Dr Kennaugh. Mr Humphris works primarily with clients in the pharmaceutical and biotechnology industries, with a focus on patent prosecution and patent litigation. He is also the director of Wrays Lawyers nationally and group head for international business development, where he coordinates the firm’s relationships with international clients. Mr Humphris holds a Bachelor of Law with Honours from the University of Adelaide, a Masters in Industrial Property from the University of Technology, Sydney, and a Bachelor of Biotechnology with Honours from Flinders University. “It’s a privilege to be the first person outside of WA to join the board, and reflects the transformation of Wrays into a firm with truly national clients and national perspective. I’m looking forward to helping further drive Wrays’ growth both in Australia and overseas,” says Mr Humphris. About Wrays Wrays was established in Perth in 1920 and is now one of Australia’s largest independent intellectual property (IP) firms. Wrays’ exceptional technical and legal experts provide services in the recognition, protection and prosecution of IP rights across a broad range of industries and technologies. Wrays is frequently shortlisted as one of the leading IP and boutique law firms in Australia. For more information, visit www.wrays.com.au. For more information or to obtain headshots: Joanna Stevens Kramer BLiNK Communications for Wrays 0408 466 410 joanna@blinkcomms.com.au Women Entrepreneur Closing Regional and STEM Gender Gaps 2017-11-14T00:49:44Z women-entrepreneur-closing-regional-and-stem-gender-gaps Household names such as Booktopia, Carmens Fine Foods and Cellarmasters started as AFR Fast 100 companies. Now a Dubbo entrepreneur closing regional and gender gaps has earned her place on the list, as one of the country’s fastest growing businesses. Meet Juliet Duffy of Regional Enviroscience. Nine years ago Juliet Duffy started this business from a garage in a rental property in Dubbo, NSW. Now, with offices in Dubbo, Wagga and Tamworth and recently in Maroochydore, Queensland, her business employs over 25 people, including 17 professional staff. Regional EnviroScience is an Occupational and Environmental Hygiene consultancy with specialties in asbestos, pollution incidents, meth lab clean-ups, contaminated sites and air, & water monitoring. EnviroScience protects the health of people and the environment through detecting and monitoring a range of contaminants in the air, water, soil and materials working with a range of public and private clients including state & federal departments and tier one civil, manufacturing and mining companies. ‘Being regionally-based,’ says Juliet Duffy, ’we understand the uniqueness of our natural environment, infrastructure and communities. Living in the towns where we work, our team has the connections and support to get the job done quickly and efficiently, and recognition of our innovative approach to meeting legislative and safety requirements has amplified our growth’. The company also specialises in naturally occurring asbestos which is prevalent in regional NSW, detecting and testing samples at their Dubbo-based NATA accredited laboratory. Typically a male dominated industry, the EnviroScience team includes two young women who are both science qualified and Licenced Asbestos Assessors, mentored by Juliet. ‘Being a woman in STEM is not without its challenges – especially with perceptions, however it has never really been a problem with on-site work’ says Juliet, ‘all of our team, contractors and clients support each other in day to day operations. It has been easy and thoroughly enjoyable to grow the business to where it is today, and without their support we wouldn’t have been able to achieve this extraordinary growth. I thank them all.’ The growth over the last four years can also be attested to Juliet’s sheer tenacity. A recent breast cancer survivor, Juliet knows how to put up a good fight and is a champion for regional businesses and the untapped expertise in regional areas. ‘Often the education and experience that lies within the regions is overlooked by decision makers in capital cities, adding great expense and additional resource use to manage projects.’ ‘I hope EnviroScience’s national recognition can contribute to breaking down some of the false perceptions that being a bush-based organisation is some sort of barrier to talent.’ Says Juliet. For the future Juliet is keen to develop new products, technologies and staff that will help keep people safe from environmental hazards, both in Australia and internationally. ‘Every day new hazards are being identified, and we strive to be on top of the impacts they can have on the communities where we live and work’. 2017 WHITE PEARL BALL CONTINUES QUEST TO SUPPORT UNDER-FUNDED BRAIN CANCER RESEARCH 2017-10-05T22:21:02Z 2017-white-pearl-ball-continues-quest-to-support-under-funded-brain-cancer-research Sydney, Australia, 6 October 2017: Sydney Neuro-Oncology Group (SNOG) today announced that BANK OF SYDNEY is joining THE WHITE PEARL BALL 2017 as its newest and biggest corporate partner. As part of the Bank’s wider commitment to support the community and charitable organisations, Bank of Sydney will have a significant presence at the Ball and is expected to provide SNOG with significant exposure across its many branches around the State and in ongoing communications with its customers. Having announced that the WHITE PEARL BALL 2017 will take place on November 11th at the Westin Sydney, SNOG will continue its important work in support of brain cancer research. Now in its 3rd year, the event raised $153,000 last year alone through the generous support of guests, donors and sponsors that attended the event. Donations collected at the Ball will fund a new brain cancer research position within SNOG. Established in 2000 by eminent neuro-surgeons, Dr Raymond Cook and Dr Michael Biggs, who were soon after joined by medical oncologist Associate Professor Helen Wheeler, SNOG’s research program is located at the Bill Walsh Cancer laboratory in the Kolling Institute of Medical Research on Sydney’s Royal North Shore Hospital campus. Dr. Cook, Dr. Biggs and Associate Professor Wheeler to this day remain on the Board, directing 100% of donations received to SNOG’s 3 Pillars - Research, Education and Patient Support. Notable contributions have also been made by Assoc. Professor Michael Back, Assoc. Professor Mustafa Khasraw, the recently appointed Dr. Jonathon Parkinson and Board members outside of the medical team. Established by Suzane Peponis-Brisimis in 2015 following the loss of her mother to a brain tumour, The White Pearl Ball has quickly become a much-anticipated event on the Sydney social calendar. “The White Pearl Ball is held in honour of all who have succumbed to brain cancer, those who are currently struggling and all their loved ones. The Ball honours the enormous contribution made by those in the medical profession who treat these patients and support their families and to the researchers who devote their lives to finding solutions,” said Suzane Peponis-Brisimis, Director of SNOG and the White Pearl Fundraiser. In addition to major prize sponsorships, the broader exposure created through the annual charity fundraiser has also seen sponsors such as Alcatel Mobile broadening their involvement with the organisation to include taking up a $35,000 PhD Scholarship, funding promising research by SNOG PhD student Angela Cho. As the leading cause of cancer death in people under 39 years and accounting for more than a third of cancer deaths in children under the age of 10, brain cancer is one of the most under-studied of all cancers. The reality is that brain cancer receives less than 5% of government funds allocated to cancer research funding. “It is truly heart-warming to witness the overwhelming support we receive from our partners and supporters each year, through sponsorships, contributions and donations. Our sincere thanks to all. We are particularly excited about partnering with Bank of Sydney for this Ball and look forward to working closely with the Bank of Sydney team. We also thank Sam Skontos and Alcatel Mobile for the significant donation made at the 2016 Ball and for the ongoing support, as a major prize donor, of the upcoming 2017 Ball.” With the newly signed partnership agreement with SNOG now official, Mr. Michaelas, CEO at Bank of Sydney, was full of praise for SNOG and the important role that it plays. “We would like to congratulate Suzane and her team for all the hard work they put into SNOG. They have inspired Bank of Sydney to get involved, and we want to encourage the community and our customers to support this effort for the well-being of patients whose lives are affected by brain cancer and their families. We are proud of this partnership and we hope that we will help attract more funds and raise awareness for SNOG” said Mr. Michaelas, CEO of Bank of Sydney. The White Pearl Ball will be held at Westin Sydney on November 11th. For tickets, donations, or if you require any further information, please contact Suzane on 0418 238 723 or email her at suzane@wpfundraiser.com.au. About the Sydney Neuro-Oncology Group: The Sydney Neuro-Oncology Group (SNOG) is a charitable organisation that aims to improve the management of brain tumours through targeted research, information sharing, constant scrutiny of treatment options and through education and ongoing support for patients and their families. For more information, go to www.snog.org.au About Bank of Sydney: Bank of Sydney has been operating in Australia under a full Banking Licence since April 2001. With branches in Sydney, Melbourne and Adelaide, we work closely and personally with our customers to understand and exceed their individual needs, which fulfils our vision to become Australia's only true relationship Bank. Bank of Sydney has a remarkable record of investing in and engaging with the broader community as part of its corporate social responsibility initiatives. For further information go to https://www.banksyd.com.au/ Gut health, immunity and relief from atopic dermatitis for infants: powerful bacteria strain in new consumer health products 2017-08-23T22:38:32Z gut-health-immunity-and-relief-from-atopic-dermatitis-for-infants-powerful-bacteria-strain-in-new-consumer-health-products A potent strain of probiotic bacteria scientifically and clinically demonstrated to reduce eczema symptoms in infants, colonise the gastrointestinal tract and help improve immunity for adults including endurance athletes is now available in a new range of Australian health products. The probiotic strain, Lactobacillus fermentum VRI-003, was originally isolated from a woman with robust gastrointestinal health and is owned by the Australian life sciences company Bioxyne. Lactobacillus fermentum VRI-003 is trademarked ‘PCC®’. This month Bioxyne launched three products formulated with PCC® – Progastrim® for gut health and immunity, Progastrim® + Vitamin C to help reduce the severity and duration of colds and flu symptoms, and proTract® for infants with atopic dermatitis (eczema). Bioxyne’s Scientific Director, cell and molecular biologist Dr Peter French, first started working on the connection between gut microbiome and immune health in 2002. “PCC® has an advantage over many other strains on the market because it produces a thick polysaccharide coat that causes the bacteria to clump, protecting the bacteria from stomach acid and bile and helping it adhere to the walls of the intestinal tract,” Dr French said. “We know from laboratory studies that PCC® is capable of colonising the intestinal tract and stimulating the areas of immune tissue in the small intestine known as Peyer’s Patches. It exhibits superior survival to other probiotics in the acidic (pH 2-4) environment found in the stomach and large intestine and it inhibits a number of human gastrointestinal pathogens.” In double blind, placebo-controlled studies*, PCC® has demonstrated: Reduction of the duration and severity of respiratory infections Reduction of the symptoms of moderate to severe atopic dermatitis (eczema) in infants Boosting of the immune response to the FluVax (flu vaccinations) improved bowel PCC® has a thick, clumpy coat which gives it a survival advantage over other, better known probiotics such as Lactobacillus acidophilus Earlier this year the Therapeutic Goods Administration (TGA) reviewed the evidence supporting the claims for PCC® ’s ability to help improve eczema symptoms in infants and confirmed that the claims comply with the requirements for listing the product on the Australian Register of Therapeutic Goods (ARTG). “Scientists are increasingly proving the connection between the gut microbiome and general health and wellbeing, in ways that extend far beyond just the gastrointestinal tract,” said Dr French. “The question now isn’t whether probiotics are good for you, but which probiotics should be consumed and for what purpose. “Consumers should look for probiotics that are of human origin, resistant to acid and bile, and that have been scientifically and clinically tested for their health claims. We are particularly pleased that the Therapeutic Goods Administration (TGA) earlier this year reviewed the evidence supporting the claims for PCC® ’s ability to help improve eczema symptoms in infants and confirmed that the claims comply with the requirements for listing the product on the Australian Register of Therapeutic Goods (ARTG). Bioxyne’s PCC® products – Progastrim® (RRP AUD$29.95), Progastrim® + Vitamin C (RRP AUD$32.95) and proTract® for atopic dermatitis (RRP AUD$27.95) - can be purchased online at www.bioxyne.com *References to clinical studies cited: Prescott S, Dunstan JA, Hale J, Breckler, Lehmann LH, Weston S, Richmond P, 2005. Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clinical & Experimental Allergy; 35(12):1557-1564. Weston S, Halbert A, Richmond P, Prescott SL, 2005. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Archives of Diseases in Childhood 90:892-897. Cox AJ, Pyne DB, Saunders PU, Fricker PA, 2008. Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes. British Journal of Sports Medicine 44:222-226. French P, Penny R, 2009. Use of probiotic bacteria as an adjuvant for an influenza vaccine. International Journal of Probiotics and Prebiotics 4(3):175-180. West NP, Pyne DB, Cripps AW, Hopkins WG, Eskesen DC, Jairath A, Christophersen CT, Conlon MA, Fricker PA, 2011. Lactobacillus fermentum (PCC®) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes. Nutrition Journal 10:30. Compelling new lung disease treatment pioneered in Victoria gains global attention alongside top researchers and drug developers 2017-08-20T22:46:22Z compelling-new-lung-disease-treatment-pioneered-in-victoria-gains-global-attention-alongside-top-researchers-and-drug-developers A novel drug treatment emerging from Victoria for the serious lung condition idiopathic pulmonary fibrosis will be spotlighted among world-leading researchers and scientists at the global IPF Summit in Boston (August 20-21). Idiopathic pulmonary fibrosis (IPF) is a rare fibrotic lung condition that causes persistent and progressive scarring of the tiny air sacs (alveoli) in the lungs, with symptoms including shortness of breath and coughing[1]. Lung Foundation Australia estimate that there are around 2,300 new cases diagnosed in in Australia every year[2]. The prognosis of IPF is very poor, with a median survival of only three to five years after diagnosis.[3] There are just two treatments on the market and the disease continues to progress in the majority of patients despite treatment.[4] The new drug, AD-114, is being developed by the Australian biotech AdAlta (ASX:1AD), using AdAlta’s proprietary ‘i-body’ technology. A phase 1 clinical trial will start next year. AD-114 differs from existing treatment options and others currently in clinical development due to its unique mode of action that targets the GPCR chemokine receptor CXCR4. AD-114 has been demonstrated to have both anti-inflammatory and anti-fibrotic activity, hitting a sweet spot for a potential therapy for IPF. The effects of AD-114 have been described by world-leading lung disease researcher Professor Cory Hogaboam (Cedars Sinai Medical Centre) as “impressive” and “providing a compelling case” for treating IPF. AdAlta CEO, Sam Cobb, has been invited to speak at the inaugural summit to showcase the novel therapeutic approach to this largely under-treated area. Ms Cobb will represent the only Australian company in the line-up of academics, international biotech and pharma speakers that include Prof Hogaboam as well as speakers from Genentech, Bristol-Myers Squibb, Celgene and Medimmune. “IPF is a disease with high unmet clinical need and we do believe AD-114 will provide the clinical community and patients with a much-needed new treatment option,” Ms Cobb said. “Although our focus with AD-114 is IPF, AD-114 has the potential to treat a wide-range of fibrotic conditions including wet age-related macular degeneration, of which there are 21,000 new cases diagnosed in Australia each year[5] and non-alcoholic fatty liver disease, which affects around 5.5 million Australians and is a precursor to nonalcoholic steatohepatitis (NASH)[6]. “That we’ve been invited to speak alongside world experts at the inaugural IPF Summit is immensely validating of the critical nature of our work.” AD-114 has received orphan drug status by the FDA, and if approved would be a first-in-class treatment. ‘Orphan’ drugs are those developed to treat a rare medical condition, and they are usually granted accelerated development and regulatory timelines. More about the IPF Summit: http://ipf-summit.com/ More about AdAlta: http://adalta.com.au/ ***END*** More about AdAlta and its i-body technology: AdAlta is an ASX listed Aussie biotech developing a new class of drugs to treat conditions with a high unmet clinical need. AdAlta is pioneering antibody technology that it calls an ‘i-body’. The size and shape of an i-body gives it an advantage over typical and existing antibody therapies, because it can penetrate and bind to a diverse range of therapeutically-relevant targets. An i-body can also survive extreme conditions. It can be boiled, dropped in acid, (other examples) and yet it remains stable and usable. An i-body, with its long binding loop, is able to target the GPCR chemokine receptor CXCR4, making it applicable to treat a range of clinical conditions including fibrosis. AD-114 is AdAlta’s lead i-body candidate for the treatment of fibrosis. Ilona Marchetta, Media and Digital Specialist @ IR Department +61 416 156 136 | Level 14, 88 Pitt St, Sydney NSW 2000 | www.irdepartment.com.au Investor and public relations | marketing | corporate and crisis communications About us: IR Department is a boutique investor relations consultancy based in Sydney, specialising in supporting small cap ASX listed companies with their engagement and communication with capital market participants. [1] Lung Foundation Australia [online] at http://lungfoundation.com.au/health-professionals/idiopathic-pulmonary-fibrosis-registry/ [accessed 3 August 2017] [2] Lung Foundation Australia [online] at http://lungfoundation.com.au/patient-support/rarelung/idiopathic-pulmonary-fibrosis-ipf/ [accessed 3 August 2017] [3] ATS, 2000; Raghu et al., 2011 [4] Tzouvelekis A, Bonella F, Spagnolo P, ‘Update on Therapeutic Management of Idiopathic Pulmonary Fibrosis’, Therapeutics and Clinical Risk Management, 2015 Mar 3;11:359-70. doi: 10.2147/TCRM.S69716. eCollection 2015 [5] Macular Degeneration Foundation [online] at https://www.mdfoundation.com.au/sites/default/files/MDBooklet_2017-04_WEB.pdf [accessed 7 August 2017] [6] The Economic Cost and Health Burden of Liver Disease in Australia (Jan 2013), Gastroenterological Society of Australia) Breaking News - ASX Listed G Medical Signs Binding MOU for US $67.5M for China Distribution 2017-07-27T00:24:14Z breaking-news-asx-listed-g-medical-signs-binding-mou-for-us-67-5m-for-china-distribution ASX Announcement 27 July 2017 G MEDICAL SIGNS BINDING MOU FOR CHINA DISTRIBUTION VALUED AT US$67.5M •Binding MOU signed with Shandong Boletong Information S&T Co. Ltd. •Agreed terms include call centre cooperation and a minimum purchase order of Smartphone Prizmaunits within the first year. •Medical and ancillary support via Nurse and Physician staffed call centres and ‘Cloud’ services. Mobile health and e-health company G Medical Innovations Holdings Ltd (“G Medical” or the “Company”) is pleased to announce it has executed a Binding Memorandum of Understanding (“Agreement”) between its subsidiary G Medical Innovations Asia Limited and Shandong Boletong Information S&T Co. Ltd. (“Boletong”), for the distribution of G Medical’s products and for call centre and ‘Cloud’ services in the People’s Republic of China. G Medical Smartphone Prizma Purchase Order Pursuant to the terms of the Agreement, Boletong has agreed to purchase a minimum quantity of units within the 1st Year of the G Medical Smartphone Prizma, and to provide associated support services for a minimum period of 60 months. Boletong will pay a pre-determined price for each unit, with the value of the agreement based on the minimum commitments being no less than US$67,500,000. The obligation to acquire the units commences on the granting of the CFDA certification to G Medical, which is currently in process. Support Services 1) Medical Services: Pursuant to the terms of the Agreement, Boletong and G Medical will set up a medical call centreproviding support services from 50-60 Nurses and 3-5 General Practising Physicians. Boletong will be responsible for the recruitment of the Nurses and General Practising Physicians, andthe establishment of the call centre. 2) ‘Cloud’ Subscription and Support Services: Pursuant to the terms of the Agreement, Boletong and/or G Medical will provide; a) Automated Cloud algorithm interpretation services, for biomedical signals 20170727_GMV - Binding MOU for China Distribution Page 2 of 3 b )Level 1 services including, Live and/or automated end-user technical support c) Level 2 services including, hardware (device) support, replacement/repairs Marketing and advertising G Medical agreed to contribute an immaterial portion of the per unit price as marketing and investment for Boletong's promotion of the products and services in China, with such payments to be set-off against payment of the purchase orders by Boletong. Non-competition Boletong and its associations are subject to non-competition restraints for the period of the Agreement, and ending five years after its termination (unless G Medical is found by a Court to have breached the Agreement). These non-competition restraints extend to competing with the products or services of G Medical. G Medical CEO Dr. Yacov Geva, commented: “I am extremely pleased to announce yet another significant relationship for G Medical within the ever-growing and lucrative Chinese territory. To have further increased our purchase commitment for our G Medical Smartphone Prizma devices, over and above our existing agreements, is an exceptional outcome with a key partner in Boletong. This adds further to our robust, multi-year revenue stream for the Company, particularly within the first year of a CFDA approval being granted”. “I have met with the executives of Boletong, and whilst in China have visited their facilities and operations. Boletong operates in 16+ provinces and works with the National Public Health care system and acts as a distributor of medical services for the government. Boletong is currently working with several large healthcare organisations such as Wanda, a medical company which is positioned in the top three in their area, and along with telecom carriers such as China Telecom. Boletong is also supported through investment from a large and reputable group in Beijing. Our team, has invested more than 3 months in bringing this MOU to fruition, during which time we were able to satisfy ourselves as to Boletong's strong financial position, their key government partnerships in place, and the ability to deliver all aspects under our agreement.” “This relationship is a significant strategic partnership, allowing the roll out the Company’s medical and ancillary support services within the Chinese territory, for both our professional call centre and Cloud based systems”. Ends Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com About Shandong Boletong Information S&T Co., Ltd Shandong Boletong Information S&T Co., Ltd. (Boletong) is a hi-tech medical and healthcare company invested by Beijing Honghui Group which has businesses in medicine, investment, drug store automation system and new energy areas, based in China. Boletong focuses on the production and sales of medical devices, membership healthcare management systems and R&D and applications for the National Basic Public Healthcare Project Solution. Boletong is currently one of the top 16 service providers for the national public healthcare system. Boletong is located in Jinan Hi-tech Technology Development Area, Shandong province. Boletong’s website is www.sdboletong.com About G Medical Innovations G Medical (ASX:GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company brings forth the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com Fellowship supports search for new disease treatments 2017-07-23T22:55:35Z fellowship-supports-search-for-new-disease-treatments La Trobe University and leading Australian biotech company AdAlta have received new funding to identify and develop potential treatments for a range of human diseases using the company’s novel class of drugs, known as i-bodies. La Trobe University’s Dr Chris Hocking has been awarded a Science and Industry Endowment Fund (SIEF) Business Fellowship worth $427,000 ($210,000 from the CSIRO), further strengthening the collaboration between La Trobe University and AdAlta. The SIEF Business Fellowship Program aims to build deeper connections and collaborations between researchers and industry, accelerate the adoption of new ideas and technology, while also helping to grow into larger and more profitable organisations. Furthermore, the program provides practical industry experience for early career researchers. The SIEF Fellowship grant will support Dr Hosking’s work with AdAlta’s Chief Scientific Officer, Professor Mick Foley, at the La Trobe Institute for Molecular Science. “Under the SIEF grant we will screen the i-body library to identify and develop new i-body candidates against difficult to access drug targets, such as complex signalling proteins called GPCRs,” Professor Foley said. “Chris is an excellent candidate for the Fellowship because he has extensive experience working with phage displays and screening libraries. Chris brings significant expertise to the AdAlta team.” La Trobe Pro Vice Chancellor Industry and Engagement, Dr Daniel Grant, congratulated Dr Hosking. “La Trobe recognises the importance of engaging with, and building strong partnerships with, innovative companies,” Dr Grant said. “We have had a longstanding and productive relationship with AdAlta and this Fellowship is a great outcome for both parties.” I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treatment of a wide range of human diseases. AdAlta pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, which was discovered initially in sharks and then developed as a human protein. More: www.AdAlta.com World Ovarian Cancer Day: Australia’s only Phase 1 ovarian cancer drug trial recruiting patients 2017-05-07T21:14:01Z world-ovarian-cancer-day-australia-s-only-phase-1-ovarian-cancer-drug-trial-recruiting-patients The only Phase I clinical trial of an ovarian cancer drug in Australia right now is still recruiting participants. The drug under trial, Cantrixil, is believed to be active against difficult-to-target cancer stem cells that are resistant to chemotherapy and lead to cancer recurrence. Three Australian hospitals are participating in the trial – Flinders Medical Centre in South Australia, Westmead Hospital in Sydney, and Icon Cancer Care in South Brisbane – along with three US hospitals. Cantrixil is being developed by listed Australian biotech company, Novogen Ltd (ASX: NRT). The phase 1 trial began in December 2016 and outcomes are expected in early 2018. World Ovarian Cancer Day is May 8. Ovarian cancer is the seventh most common cancer in women and has the lowest survival rate of any women’s cancer. It affects about one in 100 women worldwide, with about 240,000 new cases each year, and around 1,550 women expected to be diagnosed in Australia this year.  “Existing chemotherapy is only curative for about 20 percent of patients,” said Novogen CEO Dr James Garner.  “That Cantrixil has the potential to target and kill cancer stem cells remaining in the body after chemotherapy could lead to a significantly more effective treatment for sufferers. “Although most of the work on Cantrixil to date has focused on ovarian cancer, it’s not out of the question that it could be effective for other cancers.” The Cantrixil trial is being led by Associate Professor Dr Jim Coward, a medical oncologist and Associate Professor of Medicine at UQ School of Medicine and Mater Research, TRI, and based at Icon Cancer Care. Women interested in participating should discuss the Cantrixil trial with their oncologist.    More about Novogen and Cantrixil: http://www.novogen.com/researchpipeline/cantrixil ***END***   Media contact: Ilona Marchetta, ilona@irdepartment.com.au, 0416 156 136 Tech21 brings parents unlimited fun family time with Evo Play 2017-02-21T01:20:13Z tech21-brings-parents-unlimited-fun-family-time-with-evo-play SYDNEY, 21 February, 2017 – Tech21, the leader in impact protection for mobile devices has launched its new range of cases for the iPad in Australia: Evo Play. “Kids + iPads” isn’t always the safest pairing if your iPad isn’t protected, but it can certainly be one of the most fun for inquisitive minds. Whether it’s watching the latest episode of Peppa Pig or navigating through the back garden jungle discovering new wildlife, iPads can open up a world of exploration, but more often than not, a small chip here or a little crack there means that fun can be cut short. Prolong the play time and keep that shiny new look and feel to your iPad even when little fingers have put it through its paces thanks to tech21’s new iPad case, Evo Play. This comfortable and lightweight case has been designed to offer unbeatable drop protection from up to two metres, and with its iconic design, vibrant colours and handy multi-use handle, this case will remove any glimmer of fear you had in handing over your iPad to your children. This case is constructed almost entirely from tech21’s unique material, FlexShock™ Foam, meaning all sides and surfaces are protected from drops as the material moulds snugly to your iPad. Better still, the case is entirely dishwasher safe, so it’s easy to keep clean, and when it’s on your iPad, its sealed outer shell is abrasion/bite resistant, preventing any bacteria from getting in under the surface. “We’ve designed the all-new Evo Play with kids in mind. We know children love to learn, play and explore, and we recognise iPads are a great way for them to do this. However, they may not love your precious iPad back, so Evo Play is there for you,” comments Jason Roberts, CEO, tech21. “Evo Play is lightweight and comfortable for little hands to hold, yet strong enough to keep your iPad safe from tumbles and drops.” Evo Play is available in pink/purple and blue/green colours from tech21.com, RRP $79.95 for Apple iPad mini, mini 2, mini 3 & mini 4, and RRP $109.95 for Apple iPad Air 2. Much like all of tech21’s products, Evo Play comes with a simple promise: it’s rigorously tested to work harmoniously with your iPad. Like the technology it’s designed to protect, it uses the latest science, ingenious design and unbeatable user-friendliness to make advanced impact protection possible. Tech21 calls it ‘Protection Made Intelligent’. ### For further information, questions, or cases for review, please contact: Jim Barker, tech21/Poem Phone: +61 418 163 770 Email: jim@poemgroup.com.au High-res images: Download here About tech21 Since 2005, tech21 has been developing the most advanced, scientifically proven cases and screen shields for mobile, tablet and laptop devices worldwide. Tech21 combines science, engineering and British design to create products that address three core consumer benefits: style, protection and performance. As the brand evolves to continue meeting the needs of its consumers, tech21 has developed the most advanced impact protection material on the market – FlexShock™. The ultra-thin and lightweight material absorbs and dissipates force and can withstand drops up to 4 metres. In addition tech21 puts all its products through a rigorous testing program, and in an industry first has partnered with the National Physical Laboratory (NPL) to develop its testing methodology. This ensures that the tests tech21 products have to pass are overseen by independent experts. Tech21 is the number one case brand in the UK. For more information, visit tech21.com. eVestigator® Cyber Forensics Expert Simon Smith says 'POKÉMON NO' to Augmented Reality 2016-07-26T09:36:16Z evestigator-r-cyber-forensics-expert-simon-smith-says-pokemon-no-to-augmented-reality PRESS RELEASE 26/7/2016 CYBER FORENSIC EXPERT ISSUES NATIONAL SECURITY WARNING EVESTIGATOR CYBER FORENSICS EXPERT SIMON SMITH SAYS 'POKÉMON NO' TO AUGMENTED REALITY Availability for further interview / discussion TV – Aus-Wide – 24hrs notice, Radio – 8 hrs notice –© Simon Smith 0410 643 121 - forensic@evestigator.com.au. Written consent needed to reuse/quote from this release. Contact: Simon Smith. (eVestigator® aka Simon Smith, an expert in Cyber stalking and Cybercrime Investigations and a Master in Computer Digital Forensics says that our children and teenagers are severely at risk of physical, sexual and psychological harm from the use of this game) © SIMON SMITH - EVESTIGATOR® URGENT PUBLIC MEDIA RELEASE © - CREDIT & PERMISSION ASKED FOR IN WRITING BEFORE USE eVestigator®, Computer Forensics Cyber Expert – CHFI, Computer Hacking Forensics Investigator, Private Investigator Phone: 1800 CYBER I, Direct: 0410 643 121 www.evestigator.com.au www.cybersecurity.com.au www.courtexpertwitness.com.au Melbourne, July 26, 2016: Mr. Simon Smith of www.evestigator.com.au, and www.cybersecurity.com.au, a top Australian Computer Forensics expert, Cyber-crime Investigator, cyber-stalking expert and programmer of 25 years knows all too well the other side of what it looks like in a courtroom when somebody is the victim of cyber-stalking or white collar crime. He is often giving forensic evidence or reports in relation to high-tech computer crimes as an expert witness or private investigator. He has also worked on cases involving child pornography and the police, and is a strong advocate against Cyber-bullying, Cyber-stalking and Cyber-crimes civilly and criminally, and has helped hundreds of people attain justice and resolution in many cases, especially involving children and violence and forensic impersonation. As a Commonwealth Appointed Family Dispute Practitioner, with the very difficult job of dealing with awkward family disputes along with his specialised cyber forensic knowledge and cases as a private investigator, he speaks of cases where he has dealt with kidnapping, abductions, cults, poisoning and more. Never, however did Mr. Smith predict that what he calls “Cybergeddon™” would come so soon. Simon explains the term “augmented reality” in the new Pokémon game as going too far. “Imagine walking in a straight line and a cartoon character appears in front of you. That is simply what it is. A technology that draws a computer-generated image on a user's view of the real world (knowing on their phone where they are via the GPS), in this case a character or an object named a Pokémon. It then uses the camera on the back of the phone to paint the background, so it looks like there is a cartoon in your view”. He further says, “the earth is made up of various known areas comprising longitude and latitudes. These are known to the game and randomized, and the object of the game is to find Pokémon and physically step within a meter or so of it to interact, and likewise, collect other objects in the game”. He further explains that “these objects are randomly placed on or around you are on earth without any data verification”. Mr. Smith asks you to imagine your child, or teenage son or daughter walking around with head buried in their phone, jumping complete stranger’s fences, in and out of their neighbourhood, exploring places they shouldn’t be – knocking on stranger’s doors, asking if they can collect a Pokémon from their backyard. Then he asks you to “stop imagining because it is actually happening now”. He then asks you to imagine a “destination” that may be randomly picked in the game for your child to visit. Imagine if one of these stops was say in the case of America, “The Windsor Hotel in Phoenix Arizona”. Would you be concerned if you knew that in this instance, this was a halfway house for sex offenders? He also asks you to not imagine, and says, “Well, that happened too!” Mr. Smith deals with reverse cyber stalking cases all the time. Finally, he asks you to imagine that a group of bullies had a special directory which told them where a victim would be going at a certain time. It would allow them to lay a trap, and wait for the prey. Of course Mr. Smith says, “let’s not imagine - that actually happened too. In fact, only a few days after launch a gamer was robbed at gun point in dangerous unchartered neighbourhoods because the attackers knew he’d be chasing Pokémon they used game bonuses to lure there.” Mr. Smith, both as an IOS and Android programmer and cyber stalking forensic investigator and court expert witness strongly warns the community and rates this at a risk of 10/10 to any parent. He states that It could be used as a directory for stalkers and paedophiles to find children, and cause danger to society in an already understaffed and underqualified area of policing, being organised cyber-crime. Mr. Smith further states that it could even be considered the “Yellow Pages of Children and Teens” for Sex Predators – it could be easily argued that this is in fact no longer “augmented”. Mr. Smith strongly advises everyone to be conscious of the line that has just been crossed – and understand that crime is still crime even if it is hidden in what appears to be a ‘fun super-artificial method of game play’. “It is not a game anymore”, Mr. Smith strongly states. “It’s dangerous, it’s real and it is most likely in the hands of your children now”. Mr. Smith feels very passionate about the dangers he sees, in his expert opinion, he would strongly “recommend parents remove the game after doing further research” as he truly believes it crosses the line by masking serious cybercrime. He finishes by stating that, “It is ironic that people used to be afraid of the psychological effect of what violent artificial games may have on people, now I’m saying backed by evidence and experience, they should really be worried – because it has now crossed over to reality." This is general advice and not to be taken as legal advice and naturally, not all game players are likely to contribute to this conduct, this is an opinion expressed by me raising concern in this area of augmented reality. eVestigator®, Simon Smith Computer Forensics Cyber Expert – CHFI, Computer Hacking Forensics Investigator, Private Investigator © SIMON SMITH - EVESTIGATOR® URGENT PUBLIC MEDIA RELEASE © CREDIT & PERMISSION ASKED FOR IN WRITING BEFORE USE Please consider the environment before printing AUSTRALIA’S LEADING AUTHORS GATHER TO CONDEMN GOVERNMENT’S PLAN TO CREATE A CULTURE OF BOOK THIEVES 2016-05-18T22:21:03Z australia-s-leading-authors-gather-to-condemn-government-s-plan-to-create-a-culture-of-book-thieves Who: Richard Flanagan, Nikki Gemmell, Andy Griffiths, Tom Keneally to lead Alist roll call of Australian and international authors When: Thursday 19 May at 6.45pm – 6.55pm Where: Art Gallery NSW, just before the 16th annual Australian Book Industry Awards begin What: Photo opp with limited vox pops available on request. Don’t close the book on Australian stories. The Australian government is about to make significant changes to copyright, threatening the future of our Australian story. But at what cost to writers, culture and jobs? Guest ABIA presenter and Man Booker Prize winner, Richard Flanagan will deliver a speech in response to the Productivity Commission's Intellectual Property draft report around 10pm during the gala ceremony. ‘Australians deserve that their lives, experiences, country and culture be reflected in the literature that they read.’ - Thomas Keneally For more information, please contact: Emma Rusher T 0423 214 626 | emma@houseofrusher.com Gilson PIPETMAN M: Wins Red Dot Product Design Award 2016 2016-04-27T11:19:22Z gilson-pipetman-m-wins-red-dot-product-design-award-2016 Gilson just announced that their improved range of electronic PIPETMAN M pipettes, has earned a 2016 Red Dot Product Design Award for the Life Science and Medicine product category for its singular features, design and performance. These pipettes now feature guaranteed performance in repetitive pipetting mode and a programmable custom mode, enhancing results and reliability. Winning products were chosen by a panel of 41 judges composed of renowned specialists: outstanding products designers, respected design professors and specialised journalists, from all over the world. Criteria assessed were degree of innovation, ergonomics, functionality, durability, and quality. The 2016 Red Dot competition received a record number of 5,214 entries from 57 countries, across 31 categories. Gilson now guarantees accuracy and precision of the PIPETMAN M in repetitive pipetting mode and ensures reliable performance from the first to the last aliquot. In the absence of ISO recommendations for repetitive pipetting mode for air-displacement pipettes, Gilson volumetric specifications for the repetitive mode are within ISO 8655-2 recommendations for standard pipetting. PIPETMAN M is easy to use and with only two buttons you can reach all menu options including five pipetting modes: Pipet (standard mode), Reverse, Repetitive, Mix, and Custom. The new custom pipetting mode lets researchers create their own multi-step pipetting protocols, using the simple PIPETMAN M Software interface. For more information on the PIPETMAN M family of electronic pipettes, please visit: Pipetman-M-Multichannel For more information on the Gilson Pipetman M range,Please contact our team of Laboratory experts byEmail: automation@johnmorris.com.auFree call AUS. 1800 251 799 and NZ  0800 651 700NEW WEBSITE: www.johnmorrisgroup.com/AU/Laboratory About GilsonGilson is a global manufacturer and inventor of liquid handling solutions for the life sciences industry supplied by John Morris Scientific. By working closely with the scientific community, Gilson has created a complete portfolio of easy-to-use automated pipetting and chromatography instruments that enable scientists to produce verifiable data for numerous applications. With worldwide R&D, service, and support, Gilson helps the scientific community by simplifying lab life and accelerating a researcher’s pace to discovery, reproducibility and traceability. Introducing Gilson VERITY 1900 MS Detector 2016-04-26T08:04:07Z introducing-gilson-verity-1900-ms-detector Accelerate Your Rates of Discovery VERITY 1900 MS Detector is a Single QuadrupoleMass Spec Detector with Integrated Splitter and Make-up Pump Confirm molecular weight of your contents in record time for each collected fraction all along the purification process, removing any need for subsequent analytical verification. Accumulate fractions based on target mass, and benefit by: Lowering the number of fractions per prep injection Dry down Fewer Fractions Reconstitute and analyse fewer fractions Discover Unmatched Accessibility Chip-Based Mass Spectrometry Chip-based technology transforms the way in which mass spec is approached. The specialised miniature system components cause the VERITY 1900 MS Detector to: Use less energy Require minimal maintenance Offer users more benchspace Works without a roughing pump or nitrogen generator Operates significantly quieter in comparison to traditonal MS Read the brochure for our Gilson VERITY 1900 MS Detector For more information on the Gilson VERITY 1900,Please contact our team of Laboratory experts byEmail: automation@johnmorris.com.auFree call AUS. 1800 251 799 and NZ  0800 651 700NEW WEBSITE: www.johnmorrisgroup.com/AU/Laboratory About GilsonGilson is a global manufacturer and inventor of liquid handling solutions for the life sciences industry supplied by John Morris Scientific. By working closely with the scientific community, Gilson has created a complete portfolio of easy-to-use automated pipetting and chromatography instruments that enable scientists to produce verifiable data for numerous applications. With worldwide R&D, service, and support, Gilson helps the scientific community by simplifying lab life and accelerating a researcher’s pace to discovery, reproducibility and traceability. Grist for the Mill? Why Grinding Mills are Essential in the Lab 2016-04-25T07:09:27Z grist-for-the-mill-why-grinding-mills-are-essential-in-the-lab-1 Grinding mills play an essential role in most laboratories employed to crush, grind, and cleave samples for regular analysis. We recommend that when choosing your next grinding mill, please consider the: Cole-Parmer® Jar Mill without Jars Type of sample you're working with The sample capacity Desired particle size Types of Lab Grinding Mills A jar mill is able to grind practically all types of samples. Such mills are perfect for grinding high-purity laboratory samples. Jar mills can manage particle sizes of about 5 micrometers of soft or hard, brittle or fibrous sample material. You'll need to purchase jars and grinding media separately. Analytical mills and hand mills work best for hard and brittle samples. These mills help prepare soil, frozen food, dried vegetation, and other samples. Final particle size can range from 1 to 205 micrometers. When preparing cell and tissue culture, bead mills suit well. Ceramic beads are best used to prepare soft animal, plant, or human tissues whilst metal beads work better for hard tissue types. Glass beads are recommended for processing microorganisms. Garnet beads are perfect for soil and carbide beads are a great choice for microbial and soil RNA processing. Want to know more about Lab Grinding Mills?Our Technical Experts would love to hear from youAUS Freecall Ph. 1800 552 724 or  NZ Freecall Ph. 0800 651 700Email: info@johnmorris.com.auNEW WEBSITE: www.johnmorrisgroup.com/AU/ColeParmer Cole-Parmer is a leading global source of laboratory and industrial fluid handling products, instrumentation, equipment, and supplies. John Morris Scientific supplies Masterflex L/S Digital Miniflex Pumps and Cole-Parmer product lines in Australia, New Zealand and the South West Pacific, including popular brand names such as Oakton, Digi-Sense, Environmental Express, Ismatec, and more. Sigma 2-7 Centrifuge with innovations created through customer feedback 2016-04-19T10:09:08Z sigma-2-7-centrifuge-with-innovations-created-through-customer-feedback The latest innovation in the laboratory centrifuge range in the Sigma 2-7 as developed through extensive customer consultations. Important features of the 2-7 are it's stainless-steel bowl, imbalance switch, motorised lid lock, inventive blue LED run display and process dependability. An extremely quiet operator, this centrifuge will only lightly warm your specimen, which is valuable when working with for blood specimens. Presenting an adjustable, modular swing-out rotor, this centrifuge will be a welcome addition to many laboratories. The bench-top centrifuge Sigma 2-7 has a new durable multi-purpose design that caters specifically to confined labs while being simple to use plus quite to operate. Through customer feedback and surveys, ground-breaking new features have been introduced such as the impressive run display – a blue LED shines light from the instrument base toward the bench-top surface, this gives operators a clear indication of when the device is “in use” throughout each run. Another innovative feature has been developed for blood diagnostics in the medical laboratory where for tube clotting time with clot activator serum tubes, may be programmed. This optimises the workflow, since the centrifuge start can be followed by the user-definable clot time, and then centrifugation begins automatically; a buzzer and opening of the motorised lid lock indicates that centrifugation is complete. Enhancing the air ventilation offers extremely quiet operation and only minimum temperature increase of specimens even when running at full capacity and throughput. A total of ten programs are offered for convenience handling various applications and tube configurations. Features run display with blue LEDs clearly visible display easy-use large buttons minimal temperature increase during run brushless drive motor that's low maintenance motorised lid lock with automatic lid open last run memory storage 2 acceleration and deceleration curves (soft or fast) programmable clot time for serum tubes stainless steel bowl imbalance sensor emergency lid lock release window in the lid for external speed control overspeed controller according to EN 61010-2-020 RoHS conform Read this article in full on: News-Medical Please read our Sigma 2-7 brochure To discuss your Sigma 2-7 centrifuge needsPlease contact our Laboratory team today Freecall AUS. 1800 251 799 and NZ. 0800 651 700Email: info@johnmorris.com.auNEW WEBSITE: www.johnmorrisgroup.com/AU/Laboratory